News, Press Releases and Articles
04/02/20
25. August 2020 - Prof. Mark Nelson, University of Vermont PI and also the person incharge for SVDs@target project at UVM was interviewed by National Academy of Sciences to accompany an inaugural article from his research group in SVDs@target project.
Read his interview here and article here
04/02/20
02. April 2020 - Small vessel disease poorly understood but advanced magnetic resonance imaging scans can help- says Michael Stringer, Research Fellow, University of Edinburgh in an interview with The Stroke Alliance For Europe (SAFE).
March 2020 - The Stroke Alliance For Europe (SAFE) interviewed Danielle Kerkhofs, PhD candidate from the Maastricht University about Small Vessel Diseases and the work of SVDs@target.
February 2020 - Prof. Nedergaard was awarded to present the Thomas Willis Lecture
Congratulation from the whole SVDs@target-Team to this great achievement, Maiken!
If you want to know more about our studies and how patients can participate, please visit our "For Patients"-Section (NL, EN, D) or get in contact with us via the Contact Sheet.
April 2019 - Prof. Mark T. Nelson was elected as Member of the National Academy of Science
At the 156th annual Meeting of the National Academy of Science, Mark T. Nelson from the University of Vermont, USA was elected as member in the National Academy of Science.
To become a member in the National Academy of Science you have to be nominated followed by an extensive and careful vetting process.
Marks continuous eminent research over the last decades in the field of Neuroscience granded him access to this honor. Congratulations Mark, on this great achievement!
As every study site is reliant on participants, this is a very nice way to keep the participants informed. In this way, they directly can see how their effort and committment helped to improve treatments, therapies or diagnostics.
For more information about the Clinical studies in the SVDs@target project, please visit our "For Patient"-section.
March 2019 - Prof. Anne Joutel wins The Brain Prize 2019
In spring this year, Prof. Anne Joutel received the highly renowned Brain Price.
Since 2010, the Lundbeck Foundation annually awards the largest and most respected prize in Neuroscience to one or more brain researchers who have had ground-breaking impact on brain research.
In 2019 four french researchers were awarded - amongst Anne Joutel, who works at INSERM in Paris and leads the preclinical part of WP3 "Microvascular matrisome and vascular integrity in SVDs". Anne and the other awardees were awarded for their work in elucidating the hereditary of Small Vessel Disease.
For the full press release please visit The Brain Prize webpage.
Themed publication collection features SVDs@target researcher
"Small Vessels, Dementia and Chronic Diseases"
A themed collection about "Small Vessels, Dementia and Chronic Diseases" was published by the Portland Press in the Journal of Clinical Science.
This issue is the outcome of a workshop held in Glasgow 2017 with almost 30 publications including papers from four leading researchers of the SVDs@target consortium, who translate the EU-funding into visible research.
Prof. Anne Joutel from INSERM in Paris, Prof. Maiken Nedergaard from University of Copenhagen and Prof. Geert Jan Biessels from University of Utrecht contributed a paper to the collection, respectively.
Prof. Joanna Wardlaw from University of Edinburgh contributed several papers and had the honour to beginn the collection with the introductory editorial as Guest Editor.
March 2018 - Article Release of SAFE
The Stroke Alliance For Europe (SAFE) interviewed Anna Kopczak about Small Vessel Diseases and the work of SVDs@target.
European Commission International collaboration for research in prevention of stroke and dementia launched
 |
An international consortium of mostly European investigators has launched a major collaborative research program to uncover mechanisms and pathways in different forms of small vessel disease.
Stroke and dementia rank among the most pressing health issues in Europe. Cerebral small vessel diseases (SVDs) have emerged as a central link between these two major co-morbidities. SVDs account for more than 30% of strokes and at least 40% of dementia cases. They encounter multiple distinct diseases that can be separated based on their underlying genetic defects, risk factors, and clinical presentations. Despite this profound impact on human health, there are no treatments with proven efficacy against SVDs.
The new network “Small vessel diseases in a mechanistic perspective: Targets for Intervention in Stroke and Dementia (SVDs@target)” is funded through the European Union’s Horizon 2020 research and innovation programme and brings together top scientists with a wide range of complementary expertise. The academic institutions involved are the Ludwig-Maximilians-Universitaet (LMU, Munich, coordinating site), the University of Oxford and University of Edinburgh (UK), the University of Copenhagen (Denmark), INSERM (France), the University of Utrecht and University of Maastricht (The Netherlands), the University of Muenster and Technische Universitaet Muenchen (Germany), and the University of Vermont (US). The network further partners with the patient organisation Stroke Alliance for Europe (SAFE, Belgium), and with Arttic, a German company for project management.
SVDs@target partners have already made major progress in identifying key mechanisms underlying multiple SVDs. The new network involves basic scientists and academic clinicians and will make use of novel animal models and expertly phenotyped patient cohorts to identify key mechanisms common to multiple SVDs and determine how these mechanisms contribute to individual SVDs.
A major objective of the 5-year project is to identify common molecular, cellular, and physiological mechanisms that compromise the function of microvessels in different SVDs. The project will further determine how these common mechanistic defects cause brain damage and explore novel therapeutic approaches in experimental systems and in patients. The project will use state-of-the art technologies to enable the development of novel treatments and contribute to the prevention of stroke and dementia.
“This project comes at the right point in time. We are very excited about the opportunity and synergies that can be expected from this collaboration” says Martin Dichgans from LMU.
Please follow us on Twitter: @SVDs_at_target 
Please follow us on LinkedIn
